Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

BBIO

BridgeBio Pharma Inc

Feb 06 • 04:00PM ET

68.05

+4.32 6.78 %

Healthcare • Biotechnology • USA • NASD

Peers: VRTX BMRN BLUE CRSP NBIX SRPT ALNY RARE PRTA FOLD

| Held by: VTI VB IWM VBK VXF XBI IWO IBB VTWO SCHA

Index	RUT	P/E	-	EPS (ttm)	-4.19	Insider Own	14.53%	Shs Outstand	192.63M	Perf Week	-11.93%
Market Cap	13.11B	Forward P/E	-	EPS next Y	-1.58	Insider Trans	-4.79%	Shs Float	164.71M	Perf Month	-8.37%
Enterprise Value	15.18B	PEG	-	EPS next Q	-0.72	Inst Own	88.04%	Short Float	11.15%	Perf Quarter	8.60%
Income	-797.12M	P/S	37.07	EPS this Y	-19.65%	Inst Trans	0.97%	Short Ratio	7.64	Perf Half Y	48.10%
Sales	353.78M	P/B	-	EPS next Y	54.20%	ROA	-95.85%	Short Interest	18.37M	Perf YTD	-11.03%
Book/sh	-10.03	P/C	20.30	EPS next 5Y	-	ROE	-	52W High	81.32 -16.32%	Perf Year	102.89%
Cash/sh	3.35	P/FCF	-	EPS past 3/5Y	9.60% -3.04%	ROIC	-105.23%	52W Low	28.33 140.25%	Perf 3Y	596.52%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	47.10% 40.48%	Gross Margin	95.00%	Volatility	7.80% 5.11%	Perf 5Y	18.49%
Dividend TTM	-	EV/Sales	42.92	EPS Y/Y TTM	-73.59%	Oper. Margin	-168.17%	ATR (14)	3.97	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.76	Sales Y/Y TTM	62.46%	Profit Margin	-225.31%	RSI (14)	37.07	Recom	1.29
Dividend Gr. 3/5Y	- -	Current Ratio	3.88	EPS Q/Q	-10.81%	SMA20	-11.03%	Beta	1.15	Target Price	94.14
Payout	-	Debt/Eq	-	Sales Q/Q	4318.01%	SMA50	-9.49%	Rel Volume	1.90	Prev Close	63.73
Employees	730	LT Debt/Eq	-	Earnings	Oct 29 AMC	SMA200	23.91%	Avg Volume	2.41M	Price	68.05
IPO	Jun 27, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	-6.25% 13.24%	Trades		Volume	4,575,724	Change	6.78%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-28-26	Initiated	Barclays	Overweight	$157
Jan-06-26	Initiated	Morgan Stanley	Overweight	$96
Dec-11-25	Initiated	Bernstein	Outperform	$94
Jul-30-25	Resumed	Raymond James	Outperform	$56
Jul-21-25	Initiated	Truist	Buy	$66
Jul-14-25	Initiated	Jefferies	Buy	$70
Jul-09-25	Upgrade	Oppenheimer	Perform → Outperform	$60
Jun-17-25	Initiated	Wolfe Research	Outperform	$49
Mar-31-25	Initiated	Redburn Atlantic	Buy	$50
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Oct-03-24	Initiated	Oppenheimer	Perform
Sep-04-24	Initiated	Piper Sandler	Overweight	$46
Mar-21-24	Resumed	Raymond James	Outperform	$45
Jan-31-24	Initiated	BMO Capital Markets	Market Perform	$37
Dec-08-23	Initiated	Wells Fargo	Overweight	$58
Dec-08-23	Initiated	Wells Fargo	Overweight
Nov-07-23	Initiated	Citigroup	Buy	$42
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight	$50
Jul-18-23	Downgrade	Jefferies	Buy → Hold	$24 → $33
Apr-19-23	Initiated	Evercore ISI	Outperform	$40

Show Previous Ratings

Feb-06-26 02:20AM	BridgeBio (BBIO) Tumbles 15%, Mirrors Marked Bleed (Insider Monkey) +6.78%
Jan-27-26 05:10PM	CORRECTING and REPLACING -- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
04:01PM	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-23-26 07:40AM	Wells Fargo Remains a Buy on BridgeBio Pharma (BBIO) (Insider Monkey)
Jan-20-26 04:57AM	Analysts Remain Positive on BridgeBio Pharma, Inc. (BBIO) After Strong 2025 Results (Insider Monkey)
01:00AM	Loading…
Jan-16-26 01:00AM	BridgeBio Prices Offering of $550 Million Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027 (GlobeNewswire)
Jan-14-26 04:01PM	BridgeBio Continues Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027 (GlobeNewswire)
Jan-13-26 12:02AM	BridgeBio Pharma Highlights Attruby Surge, Preannounces $146M Q4 Revenue at JPM Healthcare Conference (MarketBeat)
Jan-12-26 10:30AM	BridgeBio Announces Commercial Progress, Program Updates, and 2026 Milestones at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
10:18AM	JPM Preannouncements Take Their Toll As Alnylam Slides, Tempus, Day One Pop (Investor's Business Daily)
Jan-09-26 10:18AM	BridgeBio Pharma Investor Update: PROPEL 3 Last Visit Set as Infigratinib Phase 3 Readout Nears (MarketBeat)
Jan-05-26 07:30AM	BridgeBio to Participate in the J.P. Morgan Healthcare Conference (GlobeNewswire) -6.15%
Jan-02-26 07:30AM	BridgeBio to Host Achondroplasia Investor Webinar on Friday, January 9th at 8:00 am ET (GlobeNewswire)
Dec-22-25 04:01PM	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-11-25 09:39AM	PayPal downgraded, Roku upgraded: Wall Street's top analyst calls (The Fly)
09:17AM	Loading…
09:17AM	Here Are Thursdays Top Wall Street Analyst Research Calls: American Eagle Outfitters, Ferrari, Intuitive Surgical, Roku, PayPal, Synopsis, Visa, and More (24/7 Wall St.)
09:17AM	Crypto Market 2026 Predictions: Which Coins Will 10x and Which Will Crash? (24/7 Wall St.)
Dec-10-25 12:00PM	This Hot Biotech Stock Just Set New All-Time Highs (Barchart)
Dec-02-25 08:02AM	How BridgeBio, A Top 4% Stock, Is Lining Up Dominos On Its Triple-Digit Sprint (Investor's Business Daily)
Dec-01-25 07:30AM	Should You Grab This Strong Buy Growth Stock With 56% Upside? (Barchart)
Nov-25-25 07:30AM	BridgeBio to Participate in December Investor Conferences (GlobeNewswire)
Nov-24-25 03:29PM	Biotech Stock Could Turn 4-Year Peak Into Records (Schaeffer's Research)
Nov-19-25 04:01PM	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-08-25 10:41AM	Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations (GlobeNewswire)
Nov-04-25 08:09PM	BridgeBio Pharma Inc (BBIO) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amid Rising ... (GuruFocus.com)
07:30AM	BridgeBio to Participate in November Investor Conferences (GlobeNewswire)
Nov-03-25 07:30AM	BridgeBio to Present Data from the Overall ATTR-CM Variant and V142I (V122I) Populations from ATTRibute-CM at the AHA Scientific Sessions 2025 (GlobeNewswire)
Oct-30-25 07:20PM	Analyst Report: BridgeBio Pharma, Inc. (Morningstar Research)
04:15PM	Alnylam Stock Has Almost Doubled In 2025. But It Took A Hit On Earnings. (Investor's Business Daily)
09:49AM	Alnylam Stock Has Already Doubled In 2025. But It Took A Hit On Earnings. (Investor's Business Daily)
05:15PM	Loading…
Oct-29-25 05:15PM	BridgeBio Pharma (BBIO) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
04:28PM	BridgeBio Pharma Lines Up Another 'Domino' As It Nears A Record High (Investor's Business Daily)
04:14PM	BridgeBio Pharma: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	BridgeBio Reports Third Quarter 2025 Financial Results and Business Updates (GlobeNewswire)
07:00AM	BridgeBio Reports Positive Phase 3 Topline Results for Encaleret in Patients with Autosomal Dominant Hypocalcemia Type 1 (GlobeNewswire)
03:55AM	BridgeBio chalks up another win for its rare disease research (BioPharma Dive)
Oct-28-25 04:01PM	BridgeBio to Report Phase 3 Results for Encaleret in ADH1 CALIBRATE Study on Wednesday, October 29th (GlobeNewswire)
09:14AM	BridgeBio Pharma (BBIO) Soars 17.1%: Is Further Upside Left in the Stock? (Zacks)
05:26AM	BridgeBio Pharma (BBIO) Soars to All-Time High on Stellar Drug Trial Result (Insider Monkey)
Oct-27-25 01:18PM	BridgeBios stock up as muscular dystrophy therapy meets Phase III endpoints (Clinical Trials Arena) +17.14%
07:00AM	BridgeBio Reports Positive Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study (GlobeNewswire)
04:02AM	BridgeBio to seek approval of limb-girdle drug following new study data (BioPharma Dive)
Oct-24-25 04:01PM	BridgeBio to Report Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study, along with Third Quarter 2025 Financial Results Next Week (GlobeNewswire)
Oct-13-25 12:47PM	This Pharma Play, The IBD Stock Of The Day, Is Offering Another Entry Amid 100% Advance This Year (Investor's Business Daily)
Oct-03-25 04:01PM	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-02-25 04:55PM	UBS Reaffirms Buy on BridgeBio (BBIO) With Optimism Around Attruby Launch (Insider Monkey)
09:46AM	BridgeBio Pharma, Inc. (BBIO) Retains $68 Target on Strong Launch Dynamics (Insider Monkey)
Oct-01-25 06:58PM	Analyst Report: BridgeBio Pharma, Inc. (Morningstar Research)
11:05AM	Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra? (Zacks)
Sep-29-25 04:24PM	BridgeBio, Up 80% This Year, Just Unveiled Promising News For Its Pfizer Rival (Investor's Business Daily)
10:42AM	BridgeBio's Acoramidis Cuts Risk Within Weeks In Rare Heart Condition (Benzinga)
Sep-28-25 11:20AM	BridgeBio, Up 80% This Year, Just Unveiled Promising News For Its Pfizer Rival (Investor's Business Daily)
11:15AM	Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM (GlobeNewswire)
Sep-24-25 02:12AM	H.C. Wainwright Reiterates a Buy on BridgeBio Pharma (BBIO) (Insider Monkey)
01:58AM	BridgeBio Pharma's Encaleret Shows Positive Phase 2 Results, Normalizes Calcium in Post-Surgical Hypoparathyroidism (Insider Monkey)
Sep-22-25 07:30AM	BridgeBio to Present Additional Cardiovascular Outcomes Data from ATTRibute-CM at the HFSA Annual Scientific Meeting 2025 (GlobeNewswire)
Sep-10-25 04:01PM	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-08-25 10:15AM	Can ALNY's Key Partnerships With Pharma Giants Drive Long-Term Growth? (Zacks)
Sep-06-25 02:30PM	Encaleret Showed Parathyroid Hormone-Independent Normalization of Blood and Urine Calcium in Phase 2 Proof-of-Concept Study in Post-Surgical Hypoparathyroidism (GlobeNewswire)
Sep-05-25 07:00PM	Analyst Report: BridgeBio Pharma, Inc. (Morningstar Research)
Sep-03-25 07:30AM	BridgeBio to Host Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar on Wednesday, September 10th at 8:00 am ET (GlobeNewswire)
Sep-02-25 07:03PM	Analyst Report: BridgeBio Pharma, Inc. (Morningstar Research)
07:30AM	BridgeBio to Present Phase 2 Proof-of-Concept Data for Encaleret in Post-Surgical Hypoparathyroidism (GlobeNewswire)
Aug-30-25 07:15AM	Acoramidis Demonstrates Statistically Significant Reduction in Cardiovascular Mortality (CVM) through Month 42 of the ATTRibute-CM Open Label Extension (GlobeNewswire)
Aug-28-25 11:49PM	Here's What Wall Street Thinks About BridgeBio Pharma (BBIO) (Insider Monkey) +6.01%
06:48PM	Analyst Report: BridgeBio Pharma, Inc. (Morningstar Research)
10:10AM	Can Alnylam Rely on Amvuttra to Sustain Its Rapid Sales Momentum? (Zacks)
Aug-27-25 07:30AM	BridgeBio to Participate in September Investor Conferences (GlobeNewswire)
Aug-25-25 07:30AM	BridgeBio to Present Additional Open-label Extension Data from ATTRibute-CM at ESC Congress 2025 (GlobeNewswire)
Aug-20-25 12:34AM	TD Cowen Reiterates Buy Rating on BridgeBio Pharma (BBIO) on Strong Attruby Sales (Insider Monkey)
Aug-12-25 10:56AM	Skeletal Dysplasia Market Growth Analysis 2025-2030 Featuring BioMarin Pharma, BridgeBio Pharma, Ascendis Pharma, Ipsen, QED Therapeutics and Other Major Players (GlobeNewswire)
Aug-06-25 02:18PM	Analyst Report: BridgeBio Pharma, Inc. (Morningstar Research) -8.94%
07:33AM	Helix Acquisition Corp. II Retains More than 60% of Trust Account after Redemptions in connection with Business Combination with BridgeBio Oncology Therapeutics (GlobeNewswire)
07:30AM	Nxera debuts an obesity pipeline; BridgeBio battles Alnylam for market share (BioPharma Dive)
03:29AM	BridgeBio Pharma Inc (BBIO) Q2 2025 Earnings Call Highlights: Record Revenue Surge and ... (GuruFocus.com)
Aug-05-25 05:25PM	BridgeBio Pharma (BBIO) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
04:26PM	BridgeBio Pharma: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	BridgeBio Reports Second Quarter 2025 Financial Results and Business Updates (GlobeNewswire)
Aug-04-25 09:22AM	BridgeBio Pharma Inc (BBIO) Q2 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Jul-31-25 10:00AM	Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for (Zacks)
Jul-30-25 12:37PM	Biotech Has Been Stalling. 3 Stocks That Could See Healthy Gains. (Barrons.com)
09:40AM	Peloton upgraded, Booking downgraded: Wall Street's top analyst calls (The Fly)
Jul-29-25 10:00AM	BridgeBio Pharma (BBIO) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Jul-25-25 11:29PM	Leerink Partners Maintains a Buy on BridgeBio Pharma (BBIO) With a $56 PT (Insider Monkey)
Jul-24-25 11:47PM	Truist Sees Upside in BridgeBio Pharma's (BBIO) ATTR-CM Strategy (Insider Monkey)
Jul-23-25 07:30AM	Novel Human Genetics Evidence Confirms Estimates of Genetic Prevalence, Underdiagnosis, and Potentially Greater Symptom Burden of Gain-of-Function CASR Variants Associated with ADH1 (GlobeNewswire)
Jul-22-25 07:30AM	BridgeBio to Host Second Quarter 2025 Financial Results Conference Call on Tuesday, August 5, 2025 at 4:30 pm ET (GlobeNewswire)
Jul-16-25 06:17AM	These 2 Momentum Stocks Got a Bullish Nod Heres Why They Could Reach New Highs (TipRanks)
Jul-14-25 09:32AM	Rivian downgraded, PayPal upgraded: Wall Street's top analyst calls (The Fly)
Jul-09-25 09:39AM	Microsoft upgraded, Instacart initiated: Wall Street's top analyst calls (The Fly) +6.46%
Jul-06-25 04:00AM	BridgeBio Pharma Raises $300M Through Partial European Royalty Monetization for BEYONTTRA (Insider Monkey)
Jul-02-25 10:29AM	BridgeBio (BBIO) Tanks After Selling Beyonttra Royalty Rights (Insider Monkey)
Jun-30-25 07:30AM	BridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA European Royalty (GlobeNewswire)
Jun-26-25 07:30AM	BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET (GlobeNewswire)
Jun-25-25 06:01AM	TipRanks Perfect 10 Picks: 2 Top-Scoring Stocks That Are Ticking Every Box (TipRanks)
Jun-24-25 04:25AM	Piper Sandler Reaffirms Overweight Rating on BridgeBio Ahead of Phase 3 CALIBRATE Results (Insider Monkey) +5.39%
Jun-11-25 07:54PM	BridgeBio Pharma, Inc. (BBIO) Price Target Raised to $56 from $53 at H.C. Wainwright (Insider Monkey)
Jun-05-25 08:50AM	BridgeBio price target raised to $42 from $37 at BMO Capital (TipRanks)
Jun-02-25 07:30AM	BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 (GlobeNewswire)
May-23-25 03:21PM	Rocket Cos., Middleby, Diebold Nixdorf, and More Stocks See Action From Activist Investors (Barrons.com)

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Francis Patrick McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kumar Neil	Chief Executive Officer	Jan 09 '26	Sale	77.11	40,000	3,084,313	715,686	Jan 12 09:01 PM
Kumar Neil	Chief Executive Officer	Jan 08 '26	Sale	73.97	40,000	2,958,855	735,686	Jan 12 09:01 PM
KUMAR HALDEA REVOCABLE TRUST U	Director	Jan 08 '26	Proposed Sale	74.27	120,000	8,912,400		Jan 08 04:23 PM
KUMAR HALDEA FAMILY IRREVOCABL	Director	Jan 08 '26	Proposed Sale	74.27	100,000	7,427,000		Jan 08 04:23 PM
Kumar Neil	Chief Executive Officer	Dec 15 '25	Sale	74.64	30,011	2,239,902	228,776	Dec 16 06:27 PM
NEIL KUMAR	Director	Dec 15 '25	Proposed Sale	75.15	30,011	2,255,327		Dec 15 04:23 PM
Apuli Maricel	Chief Accounting Officer	Dec 08 '25	Sale	74.26	2,000	148,520	130,297	Dec 10 07:53 AM
Kumar Neil	Chief Executive Officer	Dec 04 '25	Sale	74.40	40,000	2,975,913	775,686	Dec 08 05:54 PM
Kumar Neil	Chief Executive Officer	Dec 05 '25	Sale	73.31	40,000	2,932,563	755,686	Dec 08 05:54 PM
Kumar Neil	Chief Executive Officer	Nov 20 '25	Sale	65.84	26,156	1,722,224	228,776	Nov 24 06:46 PM
NEIL KUMAR	Director	Nov 20 '25	Proposed Sale	65.54	26,156	1,714,264		Nov 20 04:20 PM
Lo Andrew	Director	Nov 18 '25	Sale	65.69	55,000	3,613,069	50,583	Nov 19 05:08 PM
Lo Andrew	Director	Nov 17 '25	Sale	66.67	40,599	2,706,593	14,089	Nov 19 05:08 PM
Scott Randal W.	Director	Nov 17 '25	Option Exercise	16.75	10,000	167,500	21,589	Nov 19 05:06 PM
Scott Randal W.	Director	Nov 17 '25	Sale	66.65	10,000	666,465	11,589	Nov 19 05:06 PM
Trimarchi Thomas	President and CFO	Nov 17 '25	Sale	66.46	16,934	1,125,404	382,830	Nov 18 07:28 PM
ANDREW W LO	Director	Nov 18 '25	Proposed Sale	65.69	55,000	3,613,066		Nov 18 04:06 PM
ANDREW W LO	Director	Nov 17 '25	Proposed Sale	66.67	40,599	2,706,589		Nov 17 05:24 PM
RANDAL SCOTT	Director	Nov 17 '25	Proposed Sale	66.39	10,000	663,900		Nov 17 04:27 PM
THOMAS TRIMARCHI	Officer	Nov 17 '25	Proposed Sale	66.46	16,934	1,125,403		Nov 17 04:11 PM
Valantine Hannah	Director	Nov 12 '25	Option Exercise	48.45	25,484	1,234,700	32,949	Nov 14 04:50 PM
Valantine Hannah	Director	Nov 12 '25	Sale	66.07	25,484	1,683,728	7,465	Nov 14 04:50 PM
Hannah A Valantine	Director	Nov 12 '25	Proposed Sale	66.07	25,484	1,683,728		Nov 12 04:04 PM
Kumar Neil	Chief Executive Officer	Nov 06 '25	Sale	63.15	40,000	2,526,117	815,686	Nov 10 05:33 PM
Kumar Neil	Chief Executive Officer	Nov 07 '25	Sale	61.42	40,000	2,456,994	795,686	Nov 10 05:33 PM
DANIELS RONALD J	Director	Nov 06 '25	Option Exercise	34.65	61,031	2,114,724	78,022	Nov 07 06:03 PM
DANIELS RONALD J	Director	Nov 06 '25	Sale	63.72	61,031	3,888,999	16,991	Nov 07 06:03 PM
RONALD J DANIELS	Director	Nov 06 '25	Proposed Sale	63.72	61,031	3,888,999		Nov 06 04:54 PM
MCCORMICK FRANK	Director	Oct 29 '25	Sale	66.58	198,359	13,206,528	679,979	Oct 31 04:38 PM
Frank McCormick	Director	Oct 29 '25	Proposed Sale	66.58	198,359	13,206,532		Oct 29 05:59 PM
MCCORMICK FRANK	Director	Oct 27 '25	Sale	65.00	1,641	106,665	878,338	Oct 29 05:10 PM
Frank McCormick	Director	Oct 27 '25	Proposed Sale	65.00	1,641	106,665		Oct 27 04:06 PM
Kumar Neil	Chief Executive Officer	Oct 09 '25	Sale	54.80	40,000	2,192,092	835,686	Oct 10 05:40 PM
Kumar Neil	Chief Executive Officer	Oct 08 '25	Sale	54.78	40,000	2,191,350	855,686	Oct 10 05:40 PM
KUMAR HALDEA FAMILY IRREVOCABL	Director	Oct 08 '25	Proposed Sale	54.22	120,000	6,506,400		Oct 08 04:18 PM
KUMAR HALDEA REVOCABLE TRUST U	Director	Oct 08 '25	Proposed Sale	54.22	120,000	6,506,400		Oct 08 04:17 PM
MCCORMICK FRANK	Director	Sep 05 '25	Option Exercise	11.92	74,000	882,080	157,275	Sep 08 06:06 PM
MCCORMICK FRANK	Director	Sep 05 '25	Sale	53.16	74,000	3,933,544	83,275	Sep 08 06:06 PM
Kumar Neil	Chief Executive Officer	Sep 05 '25	Sale	53.05	40,000	2,122,047	875,686	Sep 08 06:05 PM
Kumar Neil	Chief Executive Officer	Sep 04 '25	Sale	51.34	40,000	2,053,788	895,686	Sep 08 06:05 PM
FRANK P. MCCORMICK	Director	Sep 05 '25	Proposed Sale	53.14	74,000	3,932,057		Sep 05 04:46 PM
Trimarchi Thomas	President and CFO	Aug 21 '25	Sale	49.48	42,237	2,090,081	421,081	Aug 22 04:58 PM
Kumar Neil	Chief Executive Officer	Aug 20 '25	Sale	48.82	26,156	1,276,927	223,090	Aug 22 04:46 PM
THOMAS TRIMARCHI	Officer	Aug 21 '25	Proposed Sale	49.48	42,237	2,090,077		Aug 21 04:10 PM
NEIL KUMAR	Director	Aug 20 '25	Proposed Sale	48.91	26,156	1,279,290		Aug 20 04:23 PM
Trimarchi Thomas	President and CFO	Aug 18 '25	Sale	50.23	17,353	871,722	463,318	Aug 19 07:40 PM
THOMAS TRIMARCHI	Officer	Aug 18 '25	Proposed Sale	50.23	17,353	871,723		Aug 18 04:03 PM
HOMCY CHARLES J	Director	Aug 08 '25	Sale	46.05	250,000	11,512,443	966,674	Aug 12 07:06 PM
HOMCY CHARLES J	Director	Aug 11 '25	Sale	48.00	50,000	2,400,000	916,674	Aug 12 07:06 PM
Apuli Maricel	Chief Accounting Officer	Aug 07 '25	Sale	45.44	1,000	45,440	141,859	Aug 11 06:29 PM
Kumar Neil	Chief Executive Officer	Aug 08 '25	Sale	46.22	40,000	1,848,828	915,686	Aug 11 06:12 PM
Kumar Neil	Chief Executive Officer	Aug 07 '25	Sale	45.45	40,000	1,818,121	935,686	Aug 11 06:12 PM
CHARLES J HOMCY	Director	Aug 11 '25	Proposed Sale	48.00	50,000	2,400,000		Aug 11 04:17 PM
CHARLES J HOMCY	Director	Aug 08 '25	Proposed Sale	46.05	250,000	11,512,420		Aug 08 05:11 PM
Ellis Andrea	Director	Aug 05 '25	Option Exercise	16.75	17,167	287,547	35,756	Aug 07 04:50 PM
Ellis Andrea	Director	Aug 05 '25	Sale	49.00	17,167	841,183	18,589	Aug 07 04:50 PM
ANDREA ELLIS	Director	Aug 05 '25	Proposed Sale	49.00	17,167	841,183		Aug 05 04:26 PM
Kumar Neil	Chief Executive Officer	Jul 02 '25	Sale	42.73	40,000	1,709,050	955,686	Jul 03 04:30 PM
Kumar Neil	Chief Executive Officer	Jul 01 '25	Sale	42.54	40,000	1,701,400	975,686	Jul 03 04:30 PM
VIKING GLOBAL INVESTORS LP	10% Owner	Jun 27 '25	Sale	44.00	3,500,000	154,000,000	18,555,375	Jul 01 07:48 PM
KUMAR HALDEA REVOCABLETRUST U/	Director	Jul 01 '25	Proposed Sale	43.18	120,000	5,181,600		Jul 01 04:31 PM
KUMAR HALDEA FAMILY IRREVOCABL	Director	Jul 01 '25	Proposed Sale	43.18	120,000	5,181,600		Jul 01 04:31 PM
Valantine Hannah	Director	Jun 26 '25	Sale	44.05	2,418	106,504	7,465	Jun 30 05:51 PM
Valantine Hannah	Director	Jun 26 '25	Sale	44.05	2,289	100,824	398	Jun 30 05:51 PM
MCCORMICK FRANK	Director	Jun 24 '25	Sale	44.23	100,000	4,422,800	879,979	Jun 26 05:08 PM
DENIS VON KAEPPLER IRA ROLLOVE	client's wife is a BoD	Jun 26 '25	Proposed Sale	44.03	1,891	83,261		Jun 26 04:19 PM
HANNAH VALANTINE & DENIS VON K	spouse of bod / bod is joint o	Jun 26 '25	Proposed Sale	44.01	1,542	67,863		Jun 26 04:16 PM
HANNAH A VALANTINE & DENIS VON	Officer	Jun 26 '25	Proposed Sale	44.11	876	38,640		Jun 26 04:14 PM
ERICKA VON KAEPPLER & DENIS VO	account owners are spouse and	Jun 26 '25	Proposed Sale	44.13	398	17,562		Jun 26 04:13 PM
MCCORMICK FRANK	Officer	Jun 24 '25	Proposed Sale	44.23	100,000	4,422,803		Jun 24 05:59 PM
Valantine Hannah	Director	Jun 10 '25	Option Exercise	16.75	4,292	71,891	6,056	Jun 11 05:00 PM
Valantine Hannah	Director	Jun 10 '25	Sale	40.00	4,292	171,680	1,764	Jun 11 05:00 PM
HANNAH A VALANTINE	Director	Jun 10 '25	Proposed Sale	40.00	4,292	171,680		Jun 10 04:01 PM
Kumar Neil	Chief Executive Officer	May 20 '25	Sale	33.40	75,000	2,504,978	4,798,447	May 20 06:06 PM
Kumar Neil	Chief Executive Officer	May 19 '25	Sale	33.33	26,156	871,764	217,404	May 20 06:06 PM
NEIL KUMAR	Director	May 19 '25	Proposed Sale	33.84	26,156	885,119		May 19 04:25 PM
KKR Genetic Disorder L.P.	10% Owner	May 12 '25	Sale	34.20	6,000,000	205,200,000	13,260,971	May 14 05:24 PM
KKR Genetic Disorder L.P.	Affiliate	May 12 '25	Proposed Sale	35.68	6,000,000	214,080,000		May 12 09:46 PM
Apuli Maricel	Chief Accounting Officer	May 02 '25	Sale	38.51	1,026	39,509	147,639	May 06 04:45 PM
Lo Andrew	Director	May 02 '25	Sale	38.50	100,000	3,849,900	105,583	May 06 04:42 PM
Lo Andrew	Director	May 02 '25	Proposed Sale	35.23	100,000	3,523,000		May 02 04:36 PM
Kumar Neil	Chief Executive Officer	Apr 22 '25	Sale	34.11	75,000	2,558,025	4,873,447	Apr 24 04:28 PM
Ellis Andrea	Director	Apr 14 '25	Option Exercise	8.45	10,000	84,500	22,000	Apr 16 05:39 PM
Ellis Andrea	Director	Apr 14 '25	Sale	35.00	10,000	350,000	12,000	Apr 16 05:39 PM
ANDREA ELLIS	Director	Apr 14 '25	Proposed Sale	35.00	10,000	350,000		Apr 14 04:21 PM
Ellis Andrea	Director	Apr 01 '25	Option Exercise	8.45	30,000	253,500	42,000	Apr 03 05:11 PM
Ellis Andrea	Director	Apr 01 '25	Sale	34.05	30,000	1,021,500	12,000	Apr 03 05:11 PM
ANDREA ELLIS	Director	Apr 01 '25	Proposed Sale	34.05	30,000	1,021,500		Apr 02 04:48 PM
Kumar Neil	Chief Executive Officer	Mar 25 '25	Sale	36.87	75,000	2,764,943	4,948,447	Mar 27 04:54 PM
Valantine Hannah	Director	Mar 06 '25	Option Exercise	16.75	12,875	215,656	14,639	Mar 10 04:43 PM
Valantine Hannah	Director	Mar 06 '25	Sale	32.58	12,875	419,500	1,764	Mar 10 04:43 PM
KKR Genetic Disorder L.P.	10% Owner	Mar 05 '25	Sale	32.96	6,000,000	197,760,000	19,260,971	Mar 07 06:09 PM
HANNAH A VALANTINE	Director	Mar 06 '25	Proposed Sale	32.58	12,875	419,500		Mar 06 04:06 PM
KKR Genetic Disorder L.P.	Affiliate	Mar 05 '25	Proposed Sale	34.97	6,000,000	209,820,000		Mar 05 09:09 PM
STEPHENSON BRIAN C	CFO and Treasurer	Feb 25 '25	Option Exercise	17.00	8,500	144,500	110,964	Feb 27 05:36 PM
STEPHENSON BRIAN C	CFO and Treasurer	Feb 25 '25	Sale	33.19	8,500	282,115	102,464	Feb 27 05:36 PM
Kumar Neil	Chief Executive Officer	Feb 25 '25	Sale	33.57	75,000	2,517,971	5,023,447	Feb 27 05:12 PM
KUMAR HALDEA REVOCABLE TRUST U	Director	Feb 25 '25	Proposed Sale	36.25	300,000	10,875,000		Feb 25 04:35 PM
BRIAN STEPHENSON	Officer	Feb 25 '25	Proposed Sale	36.25	34,000	1,232,500		Feb 25 04:34 PM
STEPHENSON BRIAN C	Secretary, Treasurer & CFO	Feb 19 '25	Sale	36.16	4,148	149,973	102,464	Feb 19 08:50 PM

Open in Screener

ALEC

Alector Inc

Feb 06 • 04:00PM ET

1.96

+0.14 7.69 %

Healthcare • Biotechnology • USA • NASD

Peers: BIIB REGN IONS VRTX SGMO SAGE ACAD LLY GILD AVXL

| Held by: VTI IWM VXF IWN SCHA VTWO IWC VHT PRFZ IWO

Index	RUT	P/E	-	EPS (ttm)	-1.07	Insider Own	30.00%	Shs Outstand	107.45M	Perf Week	3.70%
Market Cap	213.94M	Forward P/E	-	EPS next Y	-0.99	Insider Trans	-0.93%	Shs Float	76.40M	Perf Month	11.36%
Enterprise Value	-39.29M	PEG	-	EPS next Q	-0.38	Inst Own	62.67%	Short Float	8.49%	Perf Quarter	56.18%
Income	-107.74M	P/S	3.10	EPS this Y	-16.49%	Inst Trans	-13.59%	Short Ratio	4.76	Perf Half Y	34.25%
Sales	69.05M	P/B	3.65	EPS next Y	30.77%	ROA	-25.31%	Short Interest	6.49M	Perf YTD	25.64%
Book/sh	0.54	P/C	0.73	EPS next 5Y	1.36%	ROE	-121.98%	52W High	3.40 -42.35%	Perf Year	6.52%
Cash/sh	2.67	P/FCF	-	EPS past 3/5Y	-39.73% 6.31%	ROIC	-124.39%	52W Low	0.87 125.29%	Perf 3Y	-78.60%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-21.40% 36.50%	Gross Margin	86.27%	Volatility	8.14% 6.43%	Perf 5Y	-89.11%
Dividend TTM	-	EV/Sales	-0.57	EPS Y/Y TTM	37.36%	Oper. Margin	-172.76%	ATR (14)	0.12	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.76	Sales Y/Y TTM	12.26%	Profit Margin	-156.03%	RSI (14)	60.83	Recom	3.12
Dividend Gr. 3/5Y	- -	Current Ratio	3.76	EPS Q/Q	21.95%	SMA20	3.27%	Beta	0.63	Target Price	2.10
Payout	-	Debt/Eq	0.66	Sales Q/Q	-78.75%	SMA50	22.09%	Rel Volume	0.82	Prev Close	1.82
Employees	238	LT Debt/Eq	0.50	Earnings	Nov 06 AMC	SMA200	7.93%	Avg Volume	1.36M	Price	1.96
IPO	Feb 07, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	16.56% -6.52%	Trades		Volume	1,124,260	Change	7.69%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-22-25	Downgrade	William Blair	Outperform → Mkt Perform
Oct-22-25	Downgrade	TD Cowen	Buy → Hold
Oct-22-25	Downgrade	Mizuho	Outperform → Neutral	$1.50
Oct-22-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Oct-22-25	Downgrade	BTIG Research	Buy → Neutral
Jul-28-25	Upgrade	Mizuho	Neutral → Outperform	$3.50
Dec-17-24	Downgrade	Mizuho	Outperform → Neutral	$9 → $2.50
Dec-16-24	Downgrade	Stifel	Buy → Hold	$4
Dec-04-24	Downgrade	BofA Securities	Neutral → Underperform	$9 → $1
Nov-29-24	Reiterated	H.C. Wainwright	Buy	$35 → $7
Nov-26-24	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$10 → $3
Dec-14-23	Upgrade	Stifel	Hold → Buy	$8 → $15
Dec-12-23	Initiated	Deutsche Bank	Buy	$12
Sep-25-23	Initiated	Goldman	Sell	$4
Sep-22-23	Initiated	Cantor Fitzgerald	Overweight	$13
Jan-06-23	Downgrade	BofA Securities	Buy → Neutral	$24 → $12
Sep-09-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$27 → $13
Jul-07-22	Initiated	Mizuho	Buy	$15
Apr-13-22	Initiated	Goldman	Sell	$9
Mar-08-22	Downgrade	Stifel	Buy → Hold	$32 → $18

Show Previous Ratings

Dec-12-25 04:05PM	Alector Appoints Neil Berkley as Chief Financial Officer and Chief Business Officer (GlobeNewswire)
Dec-01-25 04:05PM	Alector to Participate in the Bank of America CNS Therapeutics Conference (GlobeNewswire) -7.52% -7.32%
Nov-18-25 10:33AM	Alector Stock Plummets 63% in a Month: Here's What You Need to Know (Zacks)
Nov-06-25 06:25PM	Alector (ALEC) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
05:29PM	Alector: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Loading…
04:05PM	Alector Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Oct-31-25 05:42AM	Alector Announces Topline Results from Phase 3 INFRONT-3 Clinical Trial Evaluating Latozinemab (Insider Monkey)
Oct-30-25 10:00AM	Analysts Estimate Certara, Inc. (CERT) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-29-25 10:00AM	Alector (ALEC) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Oct-22-25 07:22AM	Alector dementia drug, partnered with GSK, fails in key study (BioPharma Dive) -49.84%
Oct-21-25 04:05PM	Alector Announces Topline Results from Latozinemab Phase 3 Trial in Individuals with Frontotemporal Dementia Due to a GRN Mutation and Provides Business Update (GlobeNewswire)
Sep-16-25 08:00AM	Alector to Host Virtual Research and Development Event Highlighting PGRN Franchise and Brain Carrier Programs (GlobeNewswire) -6.76%
Sep-12-25 09:09AM	Lifecore Biomedical (LFCR) Soars 10.8%: Is Further Upside Left in the Stock? (Zacks)
Aug-28-25 08:00AM	Alector to Participate in Upcoming Healthcare Conferences (GlobeNewswire)
Aug-22-25 09:55AM	After Golden Cross, Alector (ALEC)'s Technical Outlook is Bright (Zacks) +11.01%
06:15PM	Loading…
Aug-07-25 06:15PM	Alector (ALEC) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +47.26%
05:09PM	Alector: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Alector Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Jul-31-25 11:40PM	Mizuho Upgrades Alector (ALEC) to Outperform, Raises PT to $3.50 on Q4 2025 Latozinemab Trial Anticipation (Insider Monkey) -6.88%
04:05PM	Alector to Host Second Quarter and Mid-Year 2025 Earnings Conference Call (GlobeNewswire)
Jun-13-25 04:05PM	Alector Provides Executive Leadership Update (GlobeNewswire)
Jun-03-25 08:00AM	Alector to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire) +7.25%
May-13-25 05:10PM	Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -7.50%
May-08-25 05:30PM	Iovance Biotherapeutics (IOVA) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +12.50%
04:05PM	Alector Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-06-25 08:00AM	Alector to Participate in Upcoming Healthcare Conferences (GlobeNewswire) -9.48%
Apr-21-25 08:50AM	Alector concludes enrolment in Phase II trial of Alzheimers treatment (Clinical Trials Arena) +5.79%
Apr-17-25 08:00AM	Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimers Disease (GlobeNewswire) -5.95%
Mar-28-25 04:05PM	Alector Provides Executive Leadership Update (GlobeNewswire)
Feb-27-25 12:32PM	Q4 2024 Alector Inc Earnings Call (Thomson Reuters StreetEvents)
02:24AM	Loading…
02:24AM	Alector Inc (ALEC) Q4 2024 Earnings Call Highlights: Strong Cash Position and Promising ... (GuruFocus.com)
Feb-26-25 05:55PM	Alector (ALEC) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:53PM	Alector: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Alector Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Feb-25-25 11:01AM	Alector Inc (ALEC) Q4 2024 Earnings Report Preview: What to Expect (GuruFocus.com)
08:00AM	Alector to Participate in Upcoming Healthcare Conferences (GlobeNewswire)
Feb-19-25 04:05PM	Alector to Host Fourth Quarter and Full-Year 2024 Earnings Conference Call (GlobeNewswire)
Jan-13-25 08:00AM	Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025 (GlobeNewswire)
Nov-27-24 06:50AM	Alector price target lowered to $7 from $35 at H.C. Wainwright (TipRanks)
Nov-26-24 09:00AM	Alector stock drops after Alzheimers drug fails in Phase II trial (Clinical Trials Arena) -35.10%
03:44AM	Alector turns to layoffs as Alzheimers drug fails (BioPharma Dive)
Nov-25-24 04:05PM	Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer's Disease and Provides Business Update (GlobeNewswire)
Nov-14-24 04:05PM	Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital (GlobeNewswire) -17.21%
Nov-06-24 05:50PM	Alector (ALEC) Reports Q3 Loss, Misses Revenue Estimates (Zacks) +7.63%
04:43PM	Alector: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Alector Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Sep-19-24 08:00AM	Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024) (GlobeNewswire) +8.87%
Aug-29-24 07:00AM	Alector to Participate in Upcoming Healthcare Conferences (GlobeNewswire)
Aug-23-24 07:19PM	Director Richard Scheller Sells 44,250 Shares of Alector Inc (ALEC) (GuruFocus.com)
Aug-07-24 06:15PM	Alector (ALEC) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
05:11PM	Alector: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Alector Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jul-31-24 04:05PM	Alector to Host Mid-Year Earnings Conference Call (GlobeNewswire)
Jul-28-24 08:05AM	Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference 2024 (AAIC ) (GlobeNewswire)
Jul-23-24 07:00AM	Alector to Present Data on Pipeline Focus Areas at the Alzheimer's Association International Conference (AAIC ) 2024 (GlobeNewswire)
Jun-29-24 08:43PM	Why Did Analysts Give Alector, Inc. (ALEC) a Moderate Buy Rating? (Insider Monkey)
06:30PM	10 Best Biotech Penny Stocks to Buy Now (Insider Monkey)
Jun-20-24 07:00AM	Alector to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference (GlobeNewswire)
Jun-10-24 07:00AM	Alector to Host Virtual Research and Development Event Highlighting Alector Brain Carrier Blood-Brain Barrier Technology Platform (GlobeNewswire)
Jun-03-24 07:00AM	Alector to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
May-09-24 07:00AM	Alector to Participate in Upcoming Healthcare Conferences (GlobeNewswire)
May-08-24 11:55PM	ALEC Stock Earnings: Alector Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
06:25PM	Alector (ALEC) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
05:19PM	Alector: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Alector Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Apr-25-24 10:02AM	Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know (Zacks) -8.38%
Feb-28-24 02:02PM	Q4 2023 Alector Inc Earnings Call (Thomson Reuters StreetEvents)
10:13AM	Alector, Inc. (NASDAQ:ALEC) Q4 2023 Earnings Call Transcript (Insider Monkey)
07:00AM	Alector to Participate in Upcoming Healthcare Conferences (GlobeNewswire)
Feb-27-24 04:46PM	Alector Inc (ALEC) Reports Fourth Quarter and Full Year 2023 Financial Results (GuruFocus.com) +8.18%
04:23PM	Alector: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-20-24 04:05PM	Alector to Host Fourth Quarter and Full-Year 2023 Earnings Call (GlobeNewswire)
10:00AM	Earnings Preview: Alector (ALEC) Q4 Earnings Expected to Decline (Zacks)
Feb-08-24 07:00AM	Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer's Disease (GlobeNewswire)
06:48AM	Strength Seen in Alector (ALEC): Can Its 6.0% Jump Turn into More Strength? (Zacks)
Feb-07-24 07:00AM	FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN) (GlobeNewswire) +5.96%
Jan-25-24 12:00PM	Alector (ALEC) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
Jan-23-24 07:32AM	Brain Disease Cures: 3 Neuroscience Stocks Targeting Revolutionary Breakthroughs (InvestorPlace)
Jan-19-24 09:20AM	Alector Announces Closing of Public Offering (GlobeNewswire)
Jan-17-24 08:54AM	Alector Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -14.01%
Jan-16-24 04:01PM	Alector Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Jan-08-24 01:25PM	Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024 (Investor's Business Daily) +7.34%
Dec-05-23 09:55AM	Wall Street Analysts Think Alector (ALEC) Could Surge 142.53%: Read This Before Placing a Bet (Zacks)
Nov-28-23 07:00AM	Alector to Host Two Virtual Research and Development Events Highlighting TREM2 and Progranulin Programs (GlobeNewswire)
Nov-14-23 09:35AM	Alector (ALEC) Loses -38.1% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) +14.06%
Nov-08-23 07:00AM	Alector to Participate in the Stifel Healthcare Conference (GlobeNewswire) -7.30%
Nov-07-23 06:02PM	Alector: Q3 Earnings Snapshot (Associated Press Finance) +5.12%
05:11PM	Alector Inc (ALEC) Reports Q3 2023 Financial Results with Key Clinical Advancements (GuruFocus.com)
04:05PM	Alector Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Oct-27-23 07:00AM	Alector Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN) (GlobeNewswire)
Sep-14-23 01:12AM	10% Owner Polaris Venture Management Co. VI, L.L.C. Sells 500,000 Shares of Alector Inc (GuruFocus.com)
Sep-08-23 12:10PM	Alector (ALEC) Up 7% on Finishing Enrolment in Alzheimer Study (Zacks)
Sep-07-23 07:00AM	Alector Announces Completion of Enrollment in the INVOKE-2 Phase 2 Clinical Trial of AL002, a TREM2 Monoclonal Antibody, in Individuals With Early Alzheimers Disease (GlobeNewswire) +6.76%
Aug-31-23 07:00AM	Alector to Participate in Upcoming Healthcare Conferences (GlobeNewswire)
Aug-10-23 09:55AM	Wall Street Analysts Believe Alector (ALEC) Could Rally 102%: Here's is How to Trade (Zacks)
Aug-03-23 05:45PM	Alector (ALEC) Surpasses Q2 Earnings and Revenue Estimates (Zacks) +32.38%
04:43PM	Alector: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Alector Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Jul-27-23 08:30AM	Alector to Host Mid-Year Earnings Conference Call (GlobeNewswire)

Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Wong-Sarad Grace	Principal Accounting Officer	Dec 05 '25	Sale	1.21	4,753	5,751	122,982	Dec 08 06:03 PM
GRACE WONG-SARAD	Officer	Dec 05 '25	Proposed Sale	1.21	4,753	5,751		Dec 05 04:09 PM
Wong-Sarad Grace	Principal Accounting Officer	Dec 03 '25	Sale	1.12	8,056	9,019	127,735	Dec 03 09:07 PM
Rosenthal Arnon	Chief Executive Officer	Dec 03 '25	Sale	1.12	104,347	116,827	2,420,040	Dec 03 09:06 PM
Kenkare-Mitra Sara	President and Head of R&D	Dec 03 '25	Sale	1.12	41,687	46,673	501,652	Dec 03 09:05 PM
Berkley Neil Lindsay	Chief Bus Ofcr & Interim CFO	Dec 03 '25	Sale	1.12	37,261	41,717	374,309	Dec 03 09:04 PM
Arnon Rosenthal	Officer	Dec 01 '25	Proposed Sale	1.23	92,427	113,685		Dec 01 07:53 PM
Neil L. Berkley	Officer	Dec 01 '25	Proposed Sale	1.23	32,992	40,580		Dec 01 07:50 PM
Grace Wong-Sarad	Officer	Dec 01 '25	Proposed Sale	1.23	7,085	8,715		Dec 01 07:49 PM
Sara Kenkare-Mitra	Officer	Dec 01 '25	Proposed Sale	1.23	36,914	45,404		Dec 01 07:48 PM
Wong-Sarad Grace	Principal Accounting Officer	Sep 02 '25	Sale	2.50	5,910	14,756	103,448	Sep 04 04:33 PM
Berkley Neil Lindsay	Principal Financial Officer	Sep 02 '25	Sale	2.50	15,842	39,554	346,570	Sep 04 04:32 PM
Kenkare-Mitra Sara	President and Head of R&D	Sep 02 '25	Sale	2.50	23,638	59,019	543,339	Sep 04 04:29 PM
Rosenthal Arnon	Chief Executive Officer	Sep 02 '25	Sale	2.50	51,562	128,740	2,350,220	Sep 04 04:27 PM
Neil L. Berkley	Officer	Sep 02 '25	Proposed Sale	2.35	15,426	36,251		Aug 29 06:25 PM
Arnon Rosenthal	Officer	Sep 02 '25	Proposed Sale	2.35	50,242	118,069		Aug 29 06:23 PM
Grace Wong-Sarad	Officer	Sep 02 '25	Proposed Sale	2.35	5,717	13,435		Aug 29 06:20 PM
Sara Kenkare-Mitra	Officer	Sep 02 '25	Proposed Sale	2.35	23,019	54,095		Aug 29 06:17 PM
Hammond Paula	Director	Aug 26 '25	Sale	2.36	14,000	32,998	74,909	Aug 27 06:37 PM
PAULA HAMMOND	Director	Aug 26 '25	Proposed Sale	2.36	14,000	32,997		Aug 26 04:07 PM
MARC GRASSO	Officer	Aug 08 '25	Proposed Sale	2.00	76,446	152,892		Aug 08 05:22 PM
Yaffe Kristine	Director	Jun 20 '25	Sale	1.44	1,000	1,440	95,409	Jun 23 04:05 PM
GRASSO MARC	Chief Financial Officer	Jun 02 '25	Sale	1.34	16,488	22,068	296,072	Jun 04 04:21 PM
Kenkare-Mitra Sara	President and Head of R&D	Jun 02 '25	Sale	1.34	23,890	31,974	512,252	Jun 04 04:19 PM
Rosenthal Arnon	Chief Executive Officer	Jun 02 '25	Sale	1.34	52,087	69,713	2,414,657	Jun 04 04:18 PM
Sara Kenkare-Mitra	Officer	Jun 02 '25	Proposed Sale	1.33	23,020	30,617		May 30 05:10 PM
Marc Grasso	Officer	Jun 02 '25	Proposed Sale	1.33	15,873	21,111		May 30 05:10 PM
Arnon Rosenthal	Officer	Jun 02 '25	Proposed Sale	1.33	50,242	66,822		May 30 05:10 PM
Kenkare-Mitra Sara	President and Head of R&D	Mar 03 '25	Sale	1.47	29,073	42,662	536,142	Mar 05 04:05 PM
Rosenthal Arnon	Chief Executive Officer	Mar 03 '25	Sale	1.47	40,330	59,176	2,466,744	Mar 05 04:05 PM
GRASSO MARC	Chief Financial Officer	Mar 03 '25	Sale	1.47	18,091	26,547	312,560	Mar 05 04:05 PM
Romano Gary	Chief Medical Officer	Mar 03 '25	Sale	1.47	16,306	23,927	332,977	Mar 05 04:05 PM
Arnon Rosenthal	Officer	Mar 03 '25	Proposed Sale	1.64	50,242	82,397		Feb 28 05:05 PM
Gary Romano	Officer	Mar 03 '25	Proposed Sale	1.64	14,306	23,462		Feb 28 05:05 PM
Sara Kenkare-Mitra	Officer	Mar 03 '25	Proposed Sale	1.64	25,516	41,846		Feb 28 05:05 PM
Marc Grasso	Officer	Mar 03 '25	Proposed Sale	1.64	15,873	26,032		Feb 28 05:05 PM

BBIO

BridgeBio Pharma Inc

ALEC

Alector Inc

Upgrade your FINVIZ experience